Medpace Holdings Inc. (MEDP) saw its stock drop sharply by 5.15% in after-hours trading on Monday, following the release of its fourth-quarter and full-year 2025 financial results.
The clinical research firm reported quarterly revenue and earnings that surpassed analyst expectations. However, the post-market sell-off appears driven by concerns over profitability, as the company's net income margin decreased compared to the prior year. Additionally, Medpace's revenue guidance for 2026 came in around the midpoint of analyst estimates, failing to provide a significant positive surprise to investors.